Evaluation of the Immunopharmacology of EDP1815 and EDP2939

NCT05682222 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

KLH and Imiquimod Induced Skin Inflammation in Healthy Volunteers

Interventions

DRUG: EDP1815
DRUG: EDP2939
DRUG: Placebo oral capsule

Sponsor

Evelo Biosciences, Inc.